Brought to you by 
Novartis licenses rheumatoid arthritis drug from Regeneron
29 Apr 2020
Executive Summary
Novartis AG has licensed worldwide rights (excluding Japan) to Regeneron Pharmaceuticals' (therapeutics for various serious diseases) IL-1 Trap, a rheumatoid arthritis treatment currently in Phase II trials.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis licenses rheumatoid arthritis drug from Regeneron
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice